Captor Therapeutics Spolka Akcyjna

Warsaw Stock Exchange CTX.WA

Captor Therapeutics Spolka Akcyjna EPS (Diluted) for the year ending December 31, 2023: USD -3.85

Captor Therapeutics Spolka Akcyjna EPS (Diluted) is USD -3.85 for the year ending December 31, 2023, a -110.44% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

Captor Therapeutics Spolka Akcyjna EPS (Diluted) for the year ending December 31, 2022 was USD -1.83, a 7.39% change year over year.
Captor Therapeutics Spolka Akcyjna EPS (Diluted) for the year ending December 31, 2021 was USD -1.98, a -83.65% change year over year.
Captor Therapeutics Spolka Akcyjna EPS (Diluted) for the year ending December 31, 2020 was USD -1.08, a -52.62% change year over year.
Captor Therapeutics Spolka Akcyjna EPS (Diluted) for the year ending December 31, 2019 was USD -0.71, a -94.25% change year over year.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

Warsaw Stock Exchange: CTX.WA

Captor Therapeutics Spolka Akcyjna

CEO	Dr. Thomas Shepherd Ph.D.
IPO Date	April 1, 2021
Location	Poland
Headquarters	ul. Dunska 11
Employees	105
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has five projects at the preclinical stage. The company was incorporated in 2015 and is based in Wroclaw, Poland.

Key trends

Past 5 years